Recently, the international authoritative index agency MSCI (Morgan Stanley Capital International) announced its 2024 Environmental, Social, and Governance (ESG) rating results. Based on its continuous in-depth efforts and outstanding performance in the ESG field, Sino Biopharm received an A rating for the second consecutive year, with its score further improving from the previous year, reaching a leading level among rated companies in the Chinese pharmaceutical industry.

MSCI is one of the most watched and recognized ESG index rating agencies in the global capital market today, and its rating results have become a mainstream investment reference for the international capital market. From 2021 to 2023, Sino Biopharm's MSCI ESG rating steadily improved from BB to A over three consecutive years. Receiving an A rating again this year represents the capital market's continued recognition of Sino Biopharm's practical performance in the ESG field and the Group's long-term value.

In the area of medical accessibility, Sino Biopharm focuses on the therapeutic fields of oncology, hepatology, surgery/analgesic, and respiratory diseases. Over the past three years, its key products have cumulatively treated over 150 million patients. Building on this foundation, the Group continues to focus on the R&D of rare disease drugs. Several rare disease drugs have been launched successively, safeguarding the equal health rights of more patients. Currently, the Group has more than 10 products sold in 24 countries and regions, and will actively expand into markets along the "Belt and Road" in the future, bringing the benefits of its R&D achievements to patients worldwide.

In the area of product quality and safety, Sino Biopharm considers quality management system certification an important basis for evaluating its quality management level. It actively promotes ISO 9001 quality system certification and quality management system recognition in its various domestic and international operating locations. At the same time, the Group actively assumes its responsibility as a core enterprise in the industrial chain. Since launching the "Responsible Supply Chain Construction" in 2022, after three years of continuous deep efforts, it has achieved comprehensive coverage of core suppliers and deep influence on key secondary suppliers, leading the industrial chain toward high-quality development together.

In the area of human resources development, Sino Biopharm continuously creates a diverse and inclusive workplace environment and is resolute in protecting the legitimate rights and interests of every employee. Building on this, the Group has formulated and effectively implemented an employee satisfaction improvement plan, as well as diverse internal and external further education support that aligns with employees' career development path planning. In recent years, the cohesion of the Group's employees has continuously improved, laying a solid foundation for meeting the complex challenges of international development.

In the field of environmental protection, Sino Biopharm has fully integrated the concept of green development into its production and operations. Several of its key member companies have been awarded national and provincial "Green Factory" titles. The Group is committed to promoting the reduction and harmless treatment of hazardous waste. By continuously exploring green production technologies, we ensure the effective achievement of hazardous waste reduction targets. At the same time, the Group is committed to making substantial contributions to addressing climate change. We have launched a special project for carbon neutrality goals and pathway planning, and plan to release the Sino Biopharm's carbon neutrality goals this year, aiming to provide scientific guidance for achieving carbon neutrality across the entire Group.

In the future, Sino Biopharm will adhere to the concept of sustainability. Through high-quality ESG management, it will earnestly practice the Group's mission of "improving the quality and protecting the dignity of human life", seek health and well-being for more patients, and enable more diseases to be treated. At the same time, it will promote the harmonious development of the company, employees, society, and the environment, provide strong support for the sustainable development of company, and work with and lead partners from all sectors of the industrial chain to jointly create long-term value.